Literature DB >> 9376594

Abnormalities of chromosome band 8p11 in leukemia: two clinical syndromes can be distinguished on the basis of MOZ involvement.

R C Aguiar1, A Chase, S Coulthard, D H Macdonald, M Carapeti, A Reiter, J Sohal, A Lennard, J M Goldman, N C Cross.   

Abstract

Two distinct leukemia syndromes are associated with abnormalities of chromosome band 8p11. First, a myeloproliferative disorder with features characteristic of both chronic myeloid leukemia and non-Hodgkin's lymphoma and second, an acute myeloid leukemia (AML) with French-American-British (FAB) M4/5 morphology and prominent erythrophagocytosis. The two syndromes are exemplified by a t(8;13)(p11;q12) and a t(8;16)(p11;p13), respectively, but cytogenetic variants of both have been described. Recently, the t(8;16) has been cloned and shown to fuse the MOZ gene at 8p11 to the CBP gene at 16p13. We have used fluorescence in situ hybridization (FISH), Southern blotting, and reverse transcriptase-polymerase chain reaction (RT-PCR) to refine the 8p11 breakpoint in three cases with t(8;13)(p11;q12) and in a single case of AML-M5 with a clinical picture apparently identical to that found in patients with a t(8;16), but characterized by an inv(8)(p11q13). FISH analysis was performed with several 8p11 CEPH yeast artificial chromosome (YAC) clones. YAC 782H11 was centromeric to the one case with t(8;13) tested, but was telomeric to the inv(8). YAC 847B12 was telomeric to both the t(8;13) and the inv(8), whereas YAC 829D12 was centromeric to the t(8;13), but split by the inv(8). Southern blotting and PCR of YAC 829D12 showed that it contained the MOZ gene. A 900-bp MOZ fragment encompassing the published t(8;16) breakpoint was amplified by PCR from normal peripheral blood leukocyte cDNA and used to probe Southern blots of patient DNA. A rearrangement was detected in the case with inv(8), but not in any of the three cases with t(8;13). Southern blotting with a CBP probe and RT-PCR with MOZ and CBP primers suggested that the inv(8) does not result in a cryptic MOZ-CBP fusion. It is likely, therefore, that MOZ is fused to a novel gene at 8q13 in this case. We conclude that the t(8;13) breakpoint is flanked by YACs 782H11 and 847B12 and is at least 1 Mb telomeric to MOZ. MOZ is involved, however, in a new variant of the t(8;16).

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9376594

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

Review 1.  Insight into the tumor suppressor function of CBP through the viral oncoprotein tax.

Authors:  K Van Orden; J K Nyborg
Journal:  Gene Expr       Date:  2000

2.  Case of chronic lymphocytic leukemia with unusual chromosome aberrations.

Authors:  Hui-Hua Hsiao; Yi-Hui Hung; Hui-Pin Hsiao; Shih-Bin Tseng; Hui-Jen Tsai; Yi-Chang Liu; Ta-Chih Liu; Mei-Chyn Chao; Yuli Chang; Sheng-Fung Lin
Journal:  Int J Hematol       Date:  2004-11       Impact factor: 2.490

3.  Inherited predisposition to myeloproliferative neoplasms.

Authors:  Amy V Jones; Nicholas C P Cross
Journal:  Ther Adv Hematol       Date:  2013-08

4.  The 8p11 myeloproliferative syndrome: review of literature and an illustrative case report.

Authors:  Ami Goradia; Michael Bayerl; Dennis Cornfield
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

Review 5.  Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable.

Authors:  Katerina Zoi; Nicholas C P Cross
Journal:  Int J Hematol       Date:  2014-09-12       Impact factor: 2.490

6.  RNAi screening identifies KAT8 as a key molecule important for cancer cell survival.

Authors:  Shuang Zhang; Xianhong Liu; Yong Zhang; Ying Cheng; Yang Li
Journal:  Int J Clin Exp Pathol       Date:  2013-04-15

7.  Histone Acetyltransferase KAT6A Upregulates PI3K/AKT Signaling through TRIM24 Binding.

Authors:  Deguan Lv; Feng Jia; Yanli Hou; Youzhou Sang; Angel A Alvarez; Weiwei Zhang; Wei-Qiang Gao; Bo Hu; Shi-Yuan Cheng; Jianwei Ge; Yanxin Li; Haizhong Feng
Journal:  Cancer Res       Date:  2017-10-11       Impact factor: 12.701

8.  MOZ-TIF2 inhibits transcription by nuclear receptors and p53 by impairment of CBP function.

Authors:  Karin B Kindle; Philip J F Troke; Hilary M Collins; Sachiko Matsuda; Daniela Bossi; Cristian Bellodi; Eric Kalkhoven; Paolo Salomoni; Pier Giuseppe Pelicci; Saverio Minucci; David M Heery
Journal:  Mol Cell Biol       Date:  2005-02       Impact factor: 4.272

Review 9.  A Critical Review of Animal Models Used in Acute Myeloid Leukemia Pathophysiology.

Authors:  Hala Skayneh; Batoul Jishi; Rita Hleihel; Maguy Hamieh; Nadine Darwiche; Ali Bazarbachi; Marwan El Sabban; Hiba El Hajj
Journal:  Genes (Basel)       Date:  2019-08-13       Impact factor: 4.096

10.  Directional association test reveals high-quality putative cancer driver biomarkers including noncoding RNAs.

Authors:  Hua Zhong; Mingzhou Song
Journal:  BMC Med Genomics       Date:  2019-12-30       Impact factor: 3.622

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.